In its upcoming report, Teva Pharmaceutical Industries Ltd. (TEVA) is predicted by Wall Street analysts to post quarterly earnings of $0.47 per share, reflecting a decline of 2.1% compared to the same period last year. Revenues are forecasted to be $3.97 billion, representing a year-over-year increase of 3.9%. The consensus EPS estimate for the quarter has undergone an upward revision of 1.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock. While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight. With that in mind, let's delve into the average projections of some Teva Pharmaceutical Industries metrics that are commonly tracked and projected by analysts on Wall Street. Analysts expect 'Revenue- COPAXONE- Total' to come in at $84.97 million. The estimate points to a change of -14.2% from the year-ago quarter. Analysts predict that the 'Revenue- API sales to third parties' will reach $115.17 million. The estimate indicates a change of -10% from the prior-year quarter. The collective assessment of analysts points to an estimated 'Revenue- Other- Total' of $221.49 million. The estimate points to a change of -30.4% from the year-ago quarter. The average prediction of analysts places 'Geographic Revenue- International Markets' at $615.76 million. The estimate indicates a year-over-year change of +3.1%. The consensus estimate for 'Geographic Revenue- United States' stands at $1.87 billion. The estimate indicates a year-over-year change of +8.5%. The consensus among analysts is that 'Geographic Revenue- United States- COPAXONE' will reach $32.38 million. The estimate indicates a change of +7.9% from the prior-year quarter. The combined assessment of analysts suggests that 'Geographic Revenue- United States- BENDEKA / TREANDA' will likely reach $35.39 million. The estimate points to a change of -23.1% from the year-ago quarter. Story Continues Analysts forecast 'Geographic Revenue- United States- AUSTEDO' to reach $360.74 million. The estimate points to a change of +27.9% from the year-ago quarter. Based on the collective assessment of analysts, 'Geographic Revenue- United States- Anda' should arrive at $370.89 million. The estimate suggests a change of -2.7% year over year. It is projected by analysts that the 'Geographic Revenue- Europe- COPAXONE' will reach $43.68 million. The estimate points to a change of -23.4% from the year-ago quarter. According to the collective judgment of analysts, 'Geographic Revenue- Europe- Respiratory products' should come in at $60.84 million. The estimate points to a change of -7.8% from the year-ago quarter. Analysts' assessment points toward 'Geographic Revenue- International Markets- Generic products' reaching $487.47 million. The estimate indicates a change of +2.2% from the prior-year quarter. View all Key Company Metrics for Teva Pharmaceutical Industries here>>> Over the past month, Teva Pharmaceutical Industries shares have recorded returns of +17.3% versus the Zacks S&P 500 composite's +0.4% change. Based on its Zacks Rank #3 (Hold), TEVA will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teva Pharmaceutical Industries Ltd. (TEVA):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q1 Earnings
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...